Pyrazinonindolone derivatives for treatment of triple-negative breast cancer with improved target selectivity and process of preparation thereof

The present disclosure relates to a pyrazino indolone derivative with high target selectivity for triple-negative breast cancer and a method for manufacturing the same. More specifically, the present invention relates to: a pyrazino indolone derivative which improves a fact that the target selectivi...

Full description

Saved in:
Bibliographic Details
Main Authors JUNG YOUNG SUK, LIM SOO BIN, KWAK JAE HWAN, KWON YE MI, KIM YE JIN
Format Patent
LanguageEnglish
Korean
Published 12.03.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to a pyrazino indolone derivative with high target selectivity for triple-negative breast cancer and a method for manufacturing the same. More specifically, the present invention relates to: a pyrazino indolone derivative which improves a fact that the target selectivity for conventional triple-negative breast cancer is not high, and has a significantly higher proliferation inhibitory effect than gefitinib; and a method for manufacturing the same. 본 개시내용의 삼중음성유방암에 표적선택성이 높은 피라지노인돌론 유도체 및 이의 제조방법에 관한 것이다. 보다 구체적으로, 종래 삼중음성유방암에 대한 표적선택성이 높지 않다는 점을 개선하면서 MDA-MB-468 세포의 증식 억제효과가 제피티닙보다 월등히 높은 피라지노인돌론 유도체와 이의 제조방법에 관한 것이다.
Bibliography:Application Number: KR20190109370